Chr. Olesen & Co.

Chr. Olesen & Co., also known as Chr. Olesen A/S, is a Danish ingredients company whose activities span distribution, manufacturing, product development, and pharmaceutical synthesis. The business traces its origins to 1885, when Christian Olesen opened a store in Vendsyssel in northern Jutland. It subsequently relocated to the Copenhagen area, where the company is based today in Gentofte at Jægersborg Allé 164. The enterprise remains associated with the Olesen family and, according to the available reference material, is operated by fourth-generation family members. The company serves several industrial markets rather than a consumer-facing branded-goods market. Its distribution activities cover ingredients used in animal feed, human food, and pharmaceutical products. Product categories mentioned in reference material include vitamins, amino acids, minerals, and antioxidants. These materials are supplied as functional or nutritional inputs for manufacturers and formulators. The company’s role may therefore include sourcing, regulatory support, technical application knowledge, and distribution, although the available material does not provide a detailed breakdown of its logistics network, supplier portfolio, or geographic subsidiaries. Animal-feed ingredients have historically been the largest part of the business. In 2010, feed-related ingredients represented 67 percent of company revenue, while food-industry ingredients represented 13 percent. The source does not provide the remaining revenue split or more recent financial figures, so the 2010 proportions should be treated as historical context rather than a current business profile. Chr. Olesen Synthesis is described as the company’s manufacturing arm. It develops, manufactures, and supports the registration of wet-chemical synthesis products. Its stated areas include hydromorphone, pramipexole, codeine phosphate, terbinafine, risedronate, tolfenamic acid, amphetamine derivatives, and advanced intermediates associated with buprenorphine and tamsulosin. This gives the group a more specialized pharmaceutical-chemicals capability alongside its ingredient-distribution operations. The available reference does not identify individual manufacturing sites, production volumes, regulatory approvals, or branded pharmaceutical products. The company is best understood as a business-to-business supplier and specialty manufacturer. Its value proposition rests on access to industrial ingredients, technical and regulatory capabilities, and long-term participation in the feed, food, and pharmaceutical supply chains. There is no indication in the supplied material that Chr. Olesen & Co. is a publicly listed company, and no ticker, ownership transaction, or parent group is identified. Its history, family continuity, Copenhagen-area base, and combination of distribution with chemical synthesis distinguish it from consumer brands and from pharmaceutical companies that market finished medicines directly to patients.

Chr. Olesen & Co. traces its origins to 1885, when Christian Olesen established a store in Vendsyssel, in the northern part of Jutland. The original business was later moved to the Copenhagen area. Its present location is identified as Jægersborg Allé 164 in Gentofte, reflecting the company’s development from a regional Danish trading operation into a business with multinational activities. The company’s history is characterized by continuity within the Olesen family. The available reference describes the business as being run by fourth-generation family members, although it does not identify those individuals or provide dates for each leadership transition. This family continuity forms an important part of the company’s identity, but the supplied material does not provide a detailed account of its ownership structure, legal reorganizations, acquisitions, overseas expansion, or changes in corporate form. Over time, Chr. Olesen & Co. developed beyond general trading and distribution into specialized industrial ingredients. Its activities came to include the supply of materials for animal feed, food production, and pharmaceutical manufacturing. The ingredient portfolio described in the reference material includes vitamins, amino acids, minerals, and antioxidants. These products position the company within business-to-business supply chains, where customers use purchased ingredients in feed formulations, food products, or pharmaceutical processes rather than buying finished consumer goods under the Chr. Olesen name. Animal nutrition was the company’s largest reported business area in the historical information available. In 2010, animal-feed ingredients accounted for 67 percent of revenue, while food-industry ingredients accounted for 13 percent. The figures indicate the importance of feed-related activity at that time, although no newer revenue data or complete segment breakdown is supplied. The group also established or operates Chr. Olesen Synthesis as a manufacturing-focused arm. This division is described as working with wet-chemical synthesis, product development, manufacturing, and registration support. Its named areas include hydromorphone, pramipexole, codeine phosphate, terbinafine, risedronate, tolfenamic acid, amphetamine derivatives, and advanced intermediates for buprenorphine and tamsulosin. These activities extend the company from ingredient distribution into specialized pharmaceutical chemistry and regulated supply. The available historical record does not document a single transformative merger, public offering, bankruptcy, major scandal, or consumer-facing rebrand. Instead, it presents Chr. Olesen & Co. as an established Danish family enterprise that expanded its technical and commercial scope while retaining a base in the Copenhagen area. Further research would be needed to establish the chronology of its international offices, manufacturing facilities, product registrations, subsidiaries, and recent strategic developments.

• 2010

  Animal-feed ingredients dominate reported revenue

  [1]Chr. Olesen & Co.en.wikipedia.org

  Historical segment information states that animal-feed ingredients represented 67 percent of revenue, while food-industry ingredients represented 13 percent.

• 1885

  Christian Olesen opens the original store

  [1]Chr. Olesen & Co.en.wikipedia.org

  Christian Olesen establishes the business in Vendsyssel in northern Jutland, marking the beginning of the company’s documented history.

• Relocation to the Copenhagen area

  [1]Chr. Olesen & Co.en.wikipedia.org

  The company later moves from northern Jutland to the Copenhagen area and becomes based at Jægersborg Allé 164 in Gentofte.

A family-run Danish business-to-business supplier and specialty chemical manufacturer serving animal nutrition, food production, and pharmaceutical manufacturing.

• Animal nutrition

  Animal-feed ingredients

  Chr. Olesen & Co. distributes ingredients used in animal-feed formulations. The reference material identifies feed ingredients as the company’s largest reported business area in 2010, accounting for 67 percent of revenue. The portfolio is described broadly rather than by species or formulation, and may include nutritional and functional inputs such as vitamins, amino acids, minerals, and antioxidants.

• Food ingredients

  Food ingredients

  The company distributes ingredients for the food industry, supplying business customers rather than selling finished consumer foods under its own name. Listed ingredient categories include vitamins, amino acids, minerals, and antioxidants. In the historical 2010 breakdown, food-industry ingredients represented 13 percent of revenue. Specific applications, customer brands, and current product lines are not identified in the available source.

• Pharmaceutical ingredients

  Pharmaceutical ingredients

  Chr. Olesen & Co. supplies ingredients and chemical materials for pharmaceutical manufacturing. The reference places this activity alongside its feed and food distribution businesses and names vitamins, amino acids, minerals, and antioxidants among its broader ingredient categories. The available material does not distinguish clearly between active pharmaceutical ingredients, excipients, and other process materials across the distribution portfolio.

• Pharmaceutical synthesis

  Chr. Olesen Synthesis

  Chr. Olesen Synthesis is described as the manufacturing arm of the group. It focuses on wet-chemical synthesis, product development, manufacturing, and registration-related work. Named areas include hydromorphone, pramipexole, codeine phosphate, terbinafine, risedronate, tolfenamic acid, amphetamine derivatives, and advanced intermediates for buprenorphine and tamsulosin. The source does not provide individual product specifications or production locations.

1. 1Chr. Olesen & Co.en.wikipedia.org